Compare
Champions Oncology, Inc. vs Invivyd, Inc. vs C4 Therapeutics, Inc. vs Pelthos Therapeutics Inc.
| Latest fiscal year | Champions Oncology, Inc. CSBR | Invivyd, Inc. IVVD | C4 Therapeutics, Inc. CCCC | Pelthos Therapeutics Inc. PTHS |
|---|---|---|---|---|
| Year ended | 2026-04-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $59.42M | $53.43M | $35.95M | $16.80M |
| Revenue growth (YoY) | +4.4% | +110.5% | +1.0% | n/a |
| Gross margin | 48.0% (computed) | n/a | n/a | 76.3% (computed) |
| Operating margin | -1.9% | -104.0% | -320.5% | -193.1% |
| Net margin | -2.0% | -98.2% | -292.1% | -257.9% |
| Net income | -$1.18M | -$52.49M | -$104.99M | -$43.32M |
| EPS (Diluted) | -$0.08 | -$0.30 | -$1.27 | -$23.04 |
| Operating cash flow | -$4.47M | -$58.13M | -$98.69M | -$22.59M |
| Free cash flow | -$5.04M | -$58.29M | -$99.30M | -$22.69M |
| Cash & equivalents | n/a | $226.69M | $74.60M | $17.97M |
| Total assets | $26.99M | $276.88M | $359.07M | $130.40M |
| Total liabilities | $22.92M | $35.34M | $102.49M | $91.52M |
| Shareholders' equity | $3.94M | $241.54M | $256.59M | $38.88M |
| Return on year-end equity | -29.8% | -21.7% | -40.9% | -111.4% |
| Shares outstanding | 13.89M | 281.99M | 96.91M | 3.23M |
Revenue, most recent five fiscal years
| Fiscal year | Champions Oncology, Inc. | Invivyd, Inc. | C4 Therapeutics, Inc. | Pelthos Therapeutics Inc. |
|---|---|---|---|---|
| Latest | $59.42M Ended 2026-04-30 | $53.43M Ended 2025-12-31 | $35.95M Ended 2025-12-31 | $16.80M Ended 2025-12-31 |
| 1 year earlier | $56.94M Ended 2025-04-30 | $25.38M Ended 2024-12-31 | $35.58M Ended 2024-12-31 | $0 Ended 2024-12-31 |
| 2 years earlier | $50.16M Ended 2024-04-30 | $0 Ended 2023-12-31 | $20.76M Ended 2023-12-31 | n/a |
| 3 years earlier | $53.87M Ended 2023-04-30 | n/a | $31.10M Ended 2022-12-31 | n/a |
| 4 years earlier | $49.11M Ended 2022-04-30 | n/a | $45.78M Ended 2021-12-31 | n/a |